Frazier Healthcare Partners

DirectMed Parts is the trusted and knowledgeable source for medical imaging parts and services. Specializing in CT and MRI parts and coils, DirectMed Parts understands the importance of working with service professionals to quickly and accurately deliver quality parts to their customer sites.

Day One Biopharmaceuticals is a clinical-stage biotechnology company focused on developing targeted therapies for genetically defined cancers across all ages, with an initial emphasis on pediatric patients. The company aims to bring effective cancer treatments to families by advancing therapies that can benefit both children and adults, prioritizing programs that can progress to the market rapidly. Day One pursues licensing or acquisition of promising products from research institutions and industry partners to expand its pipeline. Its lead candidate, DAY101, is an oral, brain-penetrant, highly selective type II pan-RAF kinase inhibitor designed to target cancers driven by the RAF signaling pathway. By applying insights from childhood cancer biology, the company seeks to address unmet needs in oncology and broaden access to precision therapies.

RevSpring specializes in billing and communication software designed primarily for the healthcare and financial services sectors. Its core offerings encompass data hygiene and analytics, secure document creation and delivery, multi-channel communications, electronic billing, and online payment tools. The company focuses on enhancing cash collection processes across the revenue cycle by providing dynamic and personalized communication methods, including print, online, phone, email, and text. RevSpring emphasizes compliance with various regulatory guidelines and holds multiple security certifications, ensuring adherence to privacy and security standards. Its diverse clientele spans various industries, including healthcare, receivables management, and financial services.

Curve Beam is a manufacturer that researches and designs cone beam CT imaging equipment for orthopedic specialties.

NewAmsterdam Pharma, established in 2019 and headquartered in Naarden, the Netherlands, is a late-stage biopharmaceutical company dedicated to improving patient care in cardio-metabolic disease populations. The company's primary focus is the development of transformative therapies, with its lead product, obicetrapib, being a next-generation, oral, low-dose CETP inhibitor designed to lower LDL-C levels more effectively than current treatments, particularly for patients with statin intolerance or Arteriosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally-tolerated statin therapy.

Apollo Intelligence is a company that offers technology-driven data and insight services aimed at enhancing health innovation and improving life outcomes. By developing and operating advanced data and insights platforms, Apollo Intelligence leverages global access to data and analytical tools to assist clients in the life sciences and healthcare sectors. The company's solutions facilitate informed marketing strategies and critical decision-making processes, enabling healthcare organizations to operate more efficiently and effectively. Through its data-driven approach, Apollo Intelligence aims to empower its clients to navigate the complexities of the healthcare landscape.

Pardes Biosciences is a clinical-stage biopharmaceutical company focused on addressing significant health challenges, particularly those posed by viral infections such as COVID-19. Utilizing modern reversible-covalent chemistry, the company is dedicated to discovering and developing novel oral drug candidates. Its lead product, PBI-0451, is an oral antiviral designed to treat and prevent infections caused by SARS-CoV-2, the virus responsible for COVID-19. Pardes Biosciences aims to enhance patient access to effective treatments, catering to both adult and pediatric populations, while striving to provide convenient and accessible options for those affected by life-threatening viral infections. The company is committed to contributing to global health solutions and improving patient outcomes.

SanReno Therapeutics is a biotechnology company that specializes in the development, manufacturing, and commercialization of therapies for kidney diseases and related conditions. Operating primarily in the People’s Republic of China, Hong Kong, Macau, Taiwan, and Singapore, the company is dedicated to advancing research and development in this therapeutic area. Formed as a joint venture between Chinook Therapeutics, Frazier Healthcare Partners, and Pivotal bioVenture Partners China, SanReno Therapeutics aims to create innovative solutions that enhance the quality of life for patients suffering from kidney-related ailments.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, established in 2013. The company specializes in the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a common complication of CKD, can accelerate kidney deterioration and is associated with serious health risks, including muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, positioning the company to address a significant unmet medical need in CKD management through the innovative approach of binding and removing acid from the gastrointestinal tract.

Silence Therapeutics plc is a biotechnology company based in London, specializing in the discovery and development of innovative RNA therapeutics. The company focuses on utilizing short interfering RNA (siRNA) technology to modulate gene expression and address various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. Its pipeline includes several product candidates, such as SLN124, aimed at treating iron overload disorders by silencing the TMPRSS6 gene, and SLN360, which targets the LPA gene to reduce the risk of cardiovascular diseases. Silence Therapeutics has established strategic collaborations with major organizations, including AstraZeneca, to advance the development of siRNA therapeutics across multiple disease areas. The company leverages its proprietary genetic toolkit and delivery systems to optimize therapeutic outcomes, harnessing the body's natural biological mechanisms for effective treatment.

Scout Bio, Inc. is a biotechnology company focused on advancing veterinary medicine through innovative therapies for chronic pet health conditions. Founded in 2016 and headquartered in Philadelphia, Pennsylvania, the company specializes in developing one-time treatments utilizing veterinary biotechnology and gene therapy. Scout Bio's offerings include therapies for conditions such as anemia associated with chronic kidney disease in cats, as well as a range of small molecular drugs, protein therapies, and gene therapies. Employing adeno-associated viral vector technology, Scout Bio aims to transform veterinary care by providing effective protein and monoclonal antibody therapeutics delivered through single intra-muscular injections, thereby enhancing the quality of life for pets and supporting veterinary professionals.

Radionetics Oncology is a biopharmaceutical company dedicated to the discovery and development of innovative radiotherapeutics aimed at treating various oncology indications. The company specializes in creating non-peptide and small molecule therapies that facilitate the targeted delivery of therapeutic radioisotopes to solid tumors. By focusing on these advanced treatment options, Radionetics Oncology seeks to enhance the effectiveness of cancer therapies and improve patient outcomes in oncology care.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company leverages a proprietary scientific platform to transform native immune system proteins into innovative therapeutic candidates. Its leading programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator and CD28 pathways, designed for autoimmune and inflammatory conditions, and ALPN-303, a dual antagonist of the B cell activating factor and proliferation-inducing ligand, which is vital for B cell activation and survival. Additionally, Alpine Immune Sciences has established a collaboration with Kite Pharma to explore immunotherapies targeting the immune synapse for cancer treatment.

HilleVax is a clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2021. The company specializes in the development and commercialization of innovative vaccines. Its primary focus is on HIL-214, a virus-like particle (VLP) based vaccine candidate aimed at preventing moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HilleVax is dedicated to addressing significant public health challenges through its vaccine initiatives.

Immunovant is a clinical-stage biopharmaceutical company focused on developing monoclonal antibodies for treating autoimmune diseases. Its lead candidate, IMVT-1401, targets the neonatal Fc receptor (FcRn) and is in Phase II trials for myasthenia gravis, thyroid eye disease, and warm autoimmune hemolytic anemia.

Crinetics Pharmaceuticals is a clinical-stage company focused on discovering, developing, and commercializing therapeutics targeting peptide hormone receptors for treating rare endocrine diseases and related cancers. Its lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist in Phase I trials for acromegaly and neuroendocrine tumors.

Hummingbird Bioscience employs systems biology to uncover disease mechanisms and uses computational platforms for discovering and engineering innovative biotherapeutics. Its pipeline includes HMBD-001 (anti-HER3 antibody) and HMBD-002 (anti-VISTA antibody), both in cancer treatment. The company collaborates strategically with Cancer Research UK and Amgen.

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

ESSA Pharma Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, established in 2009. The company is dedicated to developing innovative therapies for prostate cancer, particularly advanced stages of the disease. Its lead product candidate, EPI-7386, is an oral medication currently undergoing a Phase I clinical study aimed at treating patients with metastatic castration-resistant prostate cancer. ESSA's research focuses on small molecule drugs that selectively inhibit the N-terminal domain of the androgen receptor, a critical component for the growth and survival of prostate cancer cells. This strategic targeting represents a promising avenue for next-generation hormone therapy in the treatment of prostate cancer.

Seraxis is a private biotechnology company established in March 2013, with operations in both Singapore and the United States. The company has a GMP lab located in Germantown, Maryland, where a team of scientists has developed innovative cell and encapsulation technologies. Seraxis is dedicated to creating a practical cell therapy aimed at treating insulin-dependent diabetes. Their primary objective is to provide a long-term cure for patients that does not necessitate the use of immunosuppression, thereby addressing a critical need in diabetes care. By focusing on the production of insulin to regulate glucose levels, Seraxis aims to enhance the quality of life for diabetic patients through its advanced therapeutic solutions.

CSafe designs and manufactures cold chain equipment and mobile refrigeration units for pharmaceutical, biotechnology, medical device, military and public health sectors, as well as airlines and logistics providers. The company offers active air cargo systems, passive containers and packaging, and cell and gene solutions to transport temperature‑sensitive materials, along with mobile refrigeration units for on‑site or field use. It provides lease options, active qualification and validation, training, and packaging qualification services to support compliant handling and transport. CSafe serves customers through a global network of partners, service centers, support staff, sales representatives, and distributors across the United States and international markets. Founded in 1989 and based in Dayton, Ohio, CSafe focuses on enabling safe, reliable transport of temperature‑controlled bio‑pharmaceutical cargo and related goods in global supply chains.

Avadel Pharmaceuticals is a specialty pharmaceutical company focused on developing and marketing differentiated drug products. It operates internationally with headquarters in Dublin and a presence in St. Louis and Lyon. The portfolio centers on urology, central nervous system/sleep, and hospital products, including LUMRYZ, an extended-release formulation of sodium oxybate for narcolepsy-related cataplexy and excessive daytime sleepiness in adults. The company markets three sterile injectable medicines for hospital use: Akovaz for hypotension during anesthesia, Bloxiverz for reversal of non-depolarizing neuromuscular blocking agents after surgery, and Vazculep for treatment of hypotension. Avadel pursues new product development through formulation innovation and partnerships to improve patient adherence and outcomes.

Aclaris Therapeutics is a United States-based clinical-stage biopharmaceutical company focused on developing novel therapies for immuno-inflammatory diseases and dermatology, aiming to address unmet medical and aesthetic needs where treatment options are limited. The company operates two segments, therapeutics and contract research, with the therapeutics business pursuing innovative treatments for immuno-inflammatory conditions while the contract research segment provides laboratory services. Its pipeline includes Zunsemetinib, an oral MK2 inhibitor, and ATI-2138, among other drug candidates.

Sutro Biopharma is a clinical-stage biopharmaceutical company focused on developing next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF platform. Its pipeline includes STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers.

Rocket Pharmaceuticals is a biotechnology company focused on developing gene therapies for rare pediatric diseases. Its clinical-stage programs include treatments for Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and Infantile Malignant Osteopetrosis.

Inipharm Inc. is a biopharmaceutical company established in 2018 and headquartered in Bellevue, Washington. The company specializes in discovering and developing therapies for severe liver diseases. Its research focuses on small-molecule drugs that target HSD17B13, a gene implicated in various liver conditions, including nonalcoholic steatohepatitis (NASH). By modulating the activity of HSD17B13, Inipharm aims to provide innovative treatments that can significantly reduce liver damage, inflammation, and fibrosis in affected patients.

Accuity Delivery Systems, LLC specializes in providing clinical documentation, coding, and education services tailored for the healthcare sector. Established in 2015 and headquartered in New York, with an additional office in Las Vegas, the company enhances clinical documentation practices by enabling physicians to implement effective care delivery protocols. Accuity offers comprehensive coding and quality assurance services to ensure accurate reimbursement and compliance, along with educational programs aimed at hospital providers and clinical staff. The company takes a holistic approach to clinical documentation improvement, focusing on collaboration and customization to improve documentation quality while reducing audit risks. Additionally, Accuity provides business intelligence and technology services that integrate IT solutions and analytics, facilitating informed decision-making based on extensive data generated in healthcare operations.

Scholar Rock is a biopharmaceutical company dedicated to discovering and developing innovative therapies targeting dysregulated growth factors in disease microenvironments. Its proprietary platform enables the creation of monoclonal antibodies that selectively modulate these proteins at the cellular level, potentially avoiding historical challenges associated with inhibiting growth factors. The company's lead product candidate, SRK-015, is a selective inhibitor of myostatin activation for treating neuromuscular disorders like spinal muscular atrophy.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Trillium Therapeutics Inc. is a clinical-stage immuno-oncology company based in Mississauga, Canada, that specializes in developing therapies for cancer treatment. The company focuses on harnessing the immune system to combat malignancies through innovative protein therapeutics. Its lead program, TTI-621, is a SIRPaFc fusion protein currently undergoing Phase I clinical trials for advanced relapsed or refractory hematologic malignancies, solid tumors, and mycosis fungoides. Additionally, Trillium is advancing TTI-622, another SIRPaFc protein in Phase I trials, while also exploring TTI-10001, a small molecule stimulator of interferon genes agonist in the discovery phase. Originally founded in 2004, the company has undergone several name changes, reflecting its evolving focus within the biopharmaceutical sector.

MBX Biosciences is a biotechnology company focused on developing therapies for endocrine and metabolic disorders, emphasizing rare endocrine diseases with limited treatment options. It pursues discovery, development, and commercialization of first-in-class peptide therapeutics that modulate glandular hormone signaling. MBX has developed a proprietary Precision Endocrine Peptide platform to engineer peptides with extended time-action profiles and consistent drug exposure, aiming to overcome limitations of traditional peptide therapies and improve disease management. Based in Carmel, Indiana, the company advances novel peptide programs through clinical development to address unmet medical needs in endocrine and metabolic disorders.

Lassen Therapeutics is a biotechnology company focused on developing monoclonal antibodies as potential treatments for fibrosis, rare diseases, and oncology. Its lead candidate, LASN01, targets the IL-11 receptor alpha, a critical mediator in fibrosis and tumor microenvironment organization. By blocking IL-11, Lassen Therapeutics aims to offer a more effective treatment strategy compared to traditional approaches that focus on other factors, such as TGF-β and CTGF. The company's innovative biotherapeutics leverage advanced antibody technologies to address serious health conditions, ultimately improving the lives of patients suffering from these diseases.

Lengo Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative cancer treatments. It focuses on identifying and addressing mutations in cancers that are currently underserved by existing therapies, aiming to provide targeted solutions for driver mutations across various solid tumor types. This approach enables medical practitioners and pharmaceutical companies to better meet unmet therapeutic needs in oncology.

Dascena, Inc. is a healthcare technology company based in Oakland, California, that specializes in developing machine learning algorithms aimed at enhancing disease detection and improving patient care outcomes. Established in 2018, Dascena's flagship product, AlgoDiagnostics, autonomously processes electronic health record data to facilitate early intervention for conditions such as acute decompensation, sepsis, and acute kidney injury. The company focuses on addressing unmet healthcare needs through its innovative solutions in clinical decision support, point-of-care diagnostics, and biopharma companion diagnostics. By leveraging intensive clinical research, Dascena aims to enable clinical practitioners to make timely and accurate interventions, ultimately saving lives and enhancing the delivery of care.

Aspen Neuroscience develops autologous neuron replacement therapies based on induced pluripotent stem cells to treat neurological conditions, starting with Parkinson's disease. The company uses patient-specific restorative cell therapies by combining pluripotent stem cell biology with genomic approaches and artificial intelligence to address both sporadic and familial forms of Parkinson's disease, focusing on autologous neuron replacement to modify disease progression. Based in San Diego, California, the company is a development-stage biotechnology company pursuing expansion of its iPSC-based platform to other brain disorders.

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas, dedicated to the discovery and development of biologic therapeutics aimed at treating cancer and other serious diseases. The company utilizes its proprietary engineered toxin body (ETB) platform to create therapies with unique mechanisms of action that differ from traditional antibody-drug conjugates. Its lead candidate, MT-3724, is currently undergoing Phase II clinical trials for relapsed and refractory diffuse large B-cell lymphoma and non-Hodgkin’s lymphoma. Additionally, Molecular Templates is developing other candidates, including MT-4019, which targets CD38, and has a partnership with Takeda Pharmaceutical Company to create CD38-targeted therapies for multiple myeloma. The company also collaborates with Vertex Pharmaceuticals to enhance the hematopoietic stem cell transplant process through novel conditioning regimens.

Vaxcyte is a biotechnology company developing vaccines to prevent or treat infectious diseases worldwide. Its lead product is VAX-24, a 24-valent pneumococcal conjugate vaccine candidate. The company also develops vaccines targeting emerging strains of pneumococcal disease (VAX-XP), Group A Strep infections (VAX-A1), and periodontal disease (VAX-PG).

Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of therapies for cancer treatment. The company's lead candidate, entinostat, is a class I HDAC inhibitor currently in Phase III trials for advanced hormone receptor-positive, HER2-negative breast cancer. Additionally, Syndax is advancing SNDX-5613, a selective inhibitor targeting the Menin-MLL binding interaction, in Phase I/II trials for acute myeloid leukemia with specific mutations. The company also explores entinostat in combination with immunotherapies such as Keytruda and Tecentriq for various cancers, including non-small cell lung cancer and metastatic breast cancer. Furthermore, Syndax is developing axatilimab, a monoclonal antibody targeting the CSF-1 receptor, currently in trials for chronic graft-versus-host disease. The company maintains collaborative relationships with several major pharmaceutical entities and research organizations to enhance its drug development efforts. Founded in 2005, Syndax Pharmaceuticals is committed to advancing innovative treatments for patients with challenging malignancies.

EPTAM Precision Solutions, established in 1981 and located in Northfield, New Hampshire, specializes in the manufacture of high-precision plastic and metal components, primarily serving the medical device industry. The company offers a comprehensive range of services, including contract production of polymer machining parts, precision metal components, laser cutting, welding, and plastic injection molding. EPTAM also provides value-added services such as component design and engineering, program management, and process validation, which help clients navigate the challenges associated with the design for manufacturing stage. By acting as an extension of its clients' design and engineering teams, EPTAM delivers solutions tailored to meet stringent specifications and quality standards. The company has established itself as a trusted partner for leaders in various sectors, including medical devices, semiconductors, aerospace, and defense, known for its commitment to producing high-quality, tight-tolerance machined parts for mission-critical applications.

Tarsus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for ophthalmic conditions, with a pipeline that includes first-in-class candidates aimed at Demodex blepharitis and other eye diseases. Its lead program, TP-03, targets blepharitis caused by Demodex mites and is advancing through Phase IIb/III trials, alongside efforts to address meibomian gland disease. The company is also developing TP-04 for rosacea and TP-05 for Lyme prophylaxis and community malaria reduction, indicating a broader dermatology and infectious-disease focus. Tarsus pursues development across opportunities with unmet medical need, aiming to bring novel therapeutics to patients with limited treatment options. The company was founded in 2016 and is headquartered in Irvine, California.

Epizyme, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to the discovery, development, and commercialization of innovative epigenetic medicines for cancer and other serious diseases. Founded in 2007, the company has developed Tazemetostat, an approved treatment for metastatic or locally advanced epithelioid sarcoma, and is exploring its use in various combinations for other malignancies, including follicular lymphoma, diffuse large B-cell lymphoma, and platinum-resistant solid tumors. In addition to Tazemetostat, Epizyme is advancing other drug candidates, such as pinometostat for acute myeloid leukemia and acute lymphoblastic leukemia, and inhibitors targeting PRMT5 and PRMT1 for various solid tumors and blood cancers. The company collaborates with several prominent organizations in the pharmaceutical sector to enhance its research and development efforts.

REGENXBIO is a clinical-stage biotechnology company developing gene therapy product candidates using its proprietary NAV Technology Platform. This platform delivers genes to cells to address genetic defects or produce therapeutic proteins. REGENXBIO's pipeline includes RGX-314 for wet age-related macular degeneration, RGX-121 and RGX-111 for mucopolysaccharidoses, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II disease, and RGX-501 for homozygous familial hypercholesterolemia. The company also licenses its platform to other biopharmaceutical companies.

Bellus Health is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on conditions affecting the kidneys. Its lead drug candidate, KIACTA™, is designed for the treatment of AA amyloidosis, a rare condition that can result in severe renal dysfunction. Following the successful completion of a Phase 3 study, the company is collaborating with Auven Therapeutics to advance KIACTA™, which is also being explored for treating sarcoidosis, an inflammatory disease affecting the lungs. Additionally, Bellus Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome, a serious condition linked to Shiga toxin-producing E. coli, which poses significant health risks, especially for children. The company's research pipeline also includes efforts to address AL amyloidosis, another rare disease characterized by the accumulation of amyloid proteins in the body. Bellus Health aims to meet the high unmet medical needs of patients suffering from these conditions through its focused therapeutic developments.

Galera Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutics to mitigate radiotherapy-induced side effects in cancer patients. Its lead product candidate, avasopasem manganese (GC4419), is a small molecule superoxide dismutase mimetic currently in Phase III trials for treating radiation-induced severe oral mucositis in head and neck cancer patients.

IVERIC bio is a biopharmaceutical company dedicated to discovering and developing innovative treatments for retinal diseases that have significant unmet medical needs. The company is actively working on therapeutic product candidates aimed at age-related retinal diseases, as well as gene therapy product candidates designed for orphan inherited retinal diseases. By focusing on these areas, IVERIC bio aims to address critical gaps in the current treatment landscape for patients suffering from various retinal conditions.

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.

MedData, Inc. specializes in revenue cycle management and patient financial lifecycle services. Founded in 1980 and headquartered in Brecksville, Ohio, with additional offices across four states, the company provides a range of offerings that include coding and billing services, insurance follow-up and recovery, early out processing, and compliance services for Medicaid. MedData also delivers patient pay services, such as consolidated statements, and extended business office solutions that encompass accounts receivable conversions, call center outsourcing, and patient communication. The company's commitment to enhancing patient satisfaction is reflected in its various services aimed at improving the overall financial experience for patients. Formerly a subsidiary of MEDNAX, Inc., MedData has established itself as a prominent provider in its field.

Passage Bio is a gene therapy company dedicated to developing transformative treatments for rare, monogenic central nervous system disorders. It has an integrated pipeline of five AAV-delivered therapeutics and collaborates with the University of Pennsylvania's Gene Therapy Program for preclinical work.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Buffalo Grove, Illinois, that specializes in developing and commercializing innovative treatments for gastrointestinal diseases. Incorporated in 2018, the company has rights in the United States, Europe, and Canada for vonoprazan, a potassium-competitive acid blocker (P-CAB) designed to inhibit acid secretion in the stomach. Currently, vonoprazan is undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and is also being evaluated in combination with antibiotics for addressing Helicobacter pylori infection. Phathom Pharmaceuticals aims to meet the unmet medical needs of patients suffering from acid-related disorders by leveraging the expertise of its team, which comprises seasoned professionals from the gastrointestinal and pharmaceutical sectors.

CPS is a leading provider of hospital solutions, specializing in transforming operations to enhance patient care. They deliver expert services including pharmacy management, rehabilitation support, supply chain optimization, and material management to healthcare organizations.

Scout Bio, Inc. is a biotechnology company focused on advancing veterinary medicine through innovative therapies for chronic pet health conditions. Founded in 2016 and headquartered in Philadelphia, Pennsylvania, the company specializes in developing one-time treatments utilizing veterinary biotechnology and gene therapy. Scout Bio's offerings include therapies for conditions such as anemia associated with chronic kidney disease in cats, as well as a range of small molecular drugs, protein therapies, and gene therapies. Employing adeno-associated viral vector technology, Scout Bio aims to transform veterinary care by providing effective protein and monoclonal antibody therapeutics delivered through single intra-muscular injections, thereby enhancing the quality of life for pets and supporting veterinary professionals.

Imago BioSciences, Inc. is a clinical-stage biotechnology company based in Redwood City, California, founded in 2012. The company specializes in developing novel small molecule therapeutics aimed at treating hematologic diseases, including myelodysplastic syndromes, acute myelogenous leukemia, and other conditions associated with bone marrow failure. Central to its research is the enzyme lysine-specific demethylase 1 (LSD1), which is involved in the regulation of blood cell production. Imago BioSciences is focused on translating advanced scientific insights into transformative therapies that can alter the course of disease, thereby enhancing the quality and longevity of life for patients. Its lead product candidate, Bomedemstat, is an orally administered LSD1 inhibitor currently under evaluation for its potential to modify disease progression in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers.

Passage Bio is a gene therapy company dedicated to developing transformative treatments for rare, monogenic central nervous system disorders. It has an integrated pipeline of five AAV-delivered therapeutics and collaborates with the University of Pennsylvania's Gene Therapy Program for preclinical work.

Recida Therapeutics is a biotechnology company focused on developing innovative antibiotic drugs aimed at treating serious antibiotic-resistant infections. The company specializes in creating novel-class antibiotics that target the increasing challenge posed by multi-drug resistant gram-negative bacteria. Through its research and development efforts, Recida Therapeutics seeks to provide effective therapeutics that enable patients to combat potentially deadly pathogens, addressing a critical need in the healthcare landscape.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company leverages a proprietary scientific platform to transform native immune system proteins into innovative therapeutic candidates. Its leading programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator and CD28 pathways, designed for autoimmune and inflammatory conditions, and ALPN-303, a dual antagonist of the B cell activating factor and proliferation-inducing ligand, which is vital for B cell activation and survival. Additionally, Alpine Immune Sciences has established a collaboration with Kite Pharma to explore immunotherapies targeting the immune synapse for cancer treatment.

Sojournix Inc., established in 2016 and headquartered in Waltham, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for women's health and neuroendocrine disorders. Its primary focus is SJX-653, a selective neurokinin-3 (NK3) antagonist, designed as a non-hormonal treatment option for moderate to severe vasomotor symptoms associated with menopause.

Atlanta Gastroenterology Associates is a prominent gastroenterology practice based in Georgia, specializing in the diagnosis and treatment of digestive and liver diseases, including colon cancer. The organization offers a wide range of services, including gastroenterology surgeries, anesthesia management, and pathology services. Additionally, it engages in clinical research to enhance patient care. By providing comprehensive digestive healthcare solutions, Atlanta Gastroenterology Associates aims to deliver high-quality medical services at an affordable cost to patients across Georgia and the southeastern United States.

Mirum Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing therapies for debilitating liver diseases. Its primary focus is on Maralixibat, an investigational oral drug in Phase 3 trials for treating progressive familial intrahepatic cholestasis disease and Alagille syndrome.

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.

Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. Founded in 2015 and headquartered in San Diego, California, the company is focused on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K operates as a next-generation insulin sensitizer, aiming to address the underlying pathophysiology of NASH, which is characterized by fat accumulation and inflammation in the liver and can progress to severe conditions such as cirrhosis or liver cancer. Cirius Therapeutics seeks to provide innovative solutions for healthcare providers managing liver and metabolic diseases.

Krystal Biotech, Inc. is a biopharmaceutical company based in Pittsburgh, Pennsylvania, specializing in gene therapy for patients with rare skin diseases. Founded in 2015, the company develops innovative treatments using its proprietary STAR-D gene therapy platform, which targets dermatological conditions caused by genetic mutations. Its lead candidate, beremagene geperpavec (B-VEC), is in clinical development for dystrophic epidermolysis bullosa, having completed Phase I/II studies. Krystal Biotech is also advancing other product candidates, including KB105, which is in Phase I/II trials for autosomal recessive congenital ichthyosis, and KB301 and KB104, which are in preclinical stages for aesthetic skin conditions and Netherton Syndrome, respectively. Additionally, the company is exploring treatments for chronic skin diseases through its discovery-stage candidate KB5xx. Krystal Biotech aims to enhance the quality of life for patients suffering from debilitating skin disorders with its gene therapy solutions.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

ARMO BioSciences is a biotechnology company based in Redwood City, California, focused on developing immune modulatory biologic therapeutics. The company specializes in immuno-oncology, aiming to activate the immune system of cancer patients to recognize and eradicate tumors. Its pipeline includes several product candidates: AM0010, a long-acting form of interleukin 10 (IL-10) that stimulates the immune system; AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, a form of recombinant human interleukin-15 (IL-15); and AM0012, a form of recombinant human interleukin-12 (IL-12). The company was incorporated in 2010 and formerly known as Targenics.

Mavupharma Inc., founded in 2016 and headquartered in the United States, focuses on the development of non-nucleotide, conditional modulators of the STING pathway for the treatment of cancer and infectious diseases. As a subsidiary of AbbVie Inc. since July 2019, Mavupharma leverages small molecules to indirectly and conditionally modulate the STING pathway, harnessing the innate immune system. This innovative approach aims to provide effective oral bioavailable treatments, enhancing therapeutic options for cancer patients and contributing to advancements in medical care.

Outpost Medicine is a biotechnology company founded in 2016 and based in the United States, focusing on the development of novel therapeutics for urologic and gynecologic diseases and disorders. The company is dedicated to creating innovative treatments for conditions such as overactive bladder and irritable bowel syndrome. Its lead clinical-stage product candidate, OP-233, targets stress urinary incontinence, a condition characterized by involuntary urine loss during physical activities that exert pressure on weakened pelvic floor muscles or urethral sphincters. Through its research and development efforts, Outpost Medicine aims to address significant unmet medical needs in these areas.

Southside Pharmacy is a pharmacy that offers medicine sales, blood glucose testing, and surgical and fitness equipment hire services.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

Alteon Health, LLC is a healthcare management company based in The Woodlands, Texas, specializing in outsourced services for emergency departments and hospital-based urgent care centers. The company aims to enhance healthcare outcomes by offering a range of services including emergency medicine, hospitalist medicine, critical care, post-acute care, and virtual and home health services. Alteon Health focuses on patient-centered care, leveraging physician-led innovation and data-driven practices to improve the overall healthcare experience. Through strategic partnerships, it empowers healthcare providers and staff to deliver high-quality, effective care to patients.

Iterum Therapeutics is a clinical-stage pharmaceutical company focused on developing novel anti-infectives to combat multi-drug resistant pathogens. Its lead product, sulopenem, is a penem antibiotic with both oral and intravenous formulations, currently in Phase III trials for treating various urinary tract infections and intra-abdominal infections.

Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. Founded in 2015 and headquartered in San Diego, California, the company is focused on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K operates as a next-generation insulin sensitizer, aiming to address the underlying pathophysiology of NASH, which is characterized by fat accumulation and inflammation in the liver and can progress to severe conditions such as cirrhosis or liver cancer. Cirius Therapeutics seeks to provide innovative solutions for healthcare providers managing liver and metabolic diseases.

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing treatments for immune-mediated dermatological diseases. Its lead product, ZORYVE roflumilast cream, has demonstrated symptomatic improvement in plaque psoriasis patients.

Vaxcyte is a biotechnology company developing vaccines to prevent or treat infectious diseases worldwide. Its lead product is VAX-24, a 24-valent pneumococcal conjugate vaccine candidate. The company also develops vaccines targeting emerging strains of pneumococcal disease (VAX-XP), Group A Strep infections (VAX-A1), and periodontal disease (VAX-PG).

Recognized as the number one orthopedic group since 2012 by Ranking Arizona, The CORE Institute, was founded to fulfill a vision of excellence in patient care encompassing the entire spectrum of musculoskeletal and neurosciences care. Consistent with our mission, The CORE Institute delivers the best in musculoskeletal and neurological care, built upon a foundation of pioneering research, academics, community service, and a passion for excellence in patient care. It is now one of the premier patient care destinations in the World and cares for patients from around the globe.

Matrix Medical Network is a leading provider of health risk assessment and care management services tailored for Medicare Advantage plans. Established in 2001, the company specializes in conducting in-home health evaluations performed by licensed Nurse Practitioners (NPs). During these one-on-one assessments, NPs conduct non-invasive physical exams, gather detailed personal and family medical histories, and evaluate the living conditions and medications of members. This approach helps identify potential health risks that may require further medical attention. Matrix's services are supported by advanced data analytics, empowering health plans with valuable insights and recommendations for member care. With operations spanning over 30 states, Matrix has become one of the largest providers of prospective health assessments in the United States, completing over 224,000 assessments in 2012 alone. The company is headquartered in Scottsdale, Arizona, with a member-outreach Contact Center located in Clearwater, Florida.

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company leverages a proprietary scientific platform to transform native immune system proteins into innovative therapeutic candidates. Its leading programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator and CD28 pathways, designed for autoimmune and inflammatory conditions, and ALPN-303, a dual antagonist of the B cell activating factor and proliferation-inducing ligand, which is vital for B cell activation and survival. Additionally, Alpine Immune Sciences has established a collaboration with Kite Pharma to explore immunotherapies targeting the immune synapse for cancer treatment.

Iovance Biotherapeutics is a clinical-stage biotechnology company based in San Carlos, California, specializing in the development and commercialization of cancer immunotherapy products that utilize the immune system to target and eliminate cancer cells. The company's primary focus is on tumor-infiltrating lymphocyte (TIL) therapies, with its lead candidates, lifileucel and LN-145, currently undergoing Phase II clinical trials for metastatic melanoma and metastatic cervical cancer, respectively. Iovance is also exploring additional applications of TIL and peripheral blood lymphocyte therapies for various cancers, including squamous cell carcinoma of the head and neck and chronic lymphocytic leukemia, through sponsored trials and collaborative efforts with notable research institutions. Established in 2007, Iovance aims to become a leader in the innovation and delivery of TIL therapies for solid tumors, actively preparing for potential regulatory approvals and market entry in the United States.

Aptinyx Inc. is a clinical-stage biopharmaceutical company based in Evanston, Illinois, that specializes in discovering and developing innovative therapies for disorders of the brain and nervous system. Founded in 2015, the company focuses on proprietary synthetic small molecules that modulate the NMDA receptor, enhancing nerve cell communication. Aptinyx's pipeline includes NYX-2925, which is in Phase II clinical development for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, NYX-458, another NMDA receptor modulator, is undergoing Phase I studies aimed at treating cognitive impairment associated with Parkinson's disease. The company also collaborates with Allergan plc to develop a compound for major depressive disorder, highlighting its commitment to addressing significant unmet medical needs in the central nervous system arena.

Entasis Therapeutics is a biopharmaceutical company focused on developing novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria. Its pipeline includes ETX2514SUL for Acinetobacter baumannii infections, ETX0282CPDP for Enterobacteriaceae infections, and zoliflodacin for Neisseria gonorrhoeae.

Zavante Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in developing innovative therapies for patients in hospital settings. Founded in 2013, Zavante is focused on creating treatments that address serious and life-threatening infections, particularly those caused by multi-drug resistant bacteria. One of its key pipeline products is ZOLYD, an investigational injectable antibiotic designed to combat these challenging infections. The company's commitment to improving patient outcomes highlights its role in addressing critical healthcare needs within the hospital environment.

Iterum Therapeutics is a clinical-stage pharmaceutical company focused on developing novel anti-infectives to combat multi-drug resistant pathogens. Its lead product, sulopenem, is a penem antibiotic with both oral and intravenous formulations, currently in Phase III trials for treating various urinary tract infections and intra-abdominal infections.

Outpost Medicine is a biotechnology company founded in 2016 and based in the United States, focusing on the development of novel therapeutics for urologic and gynecologic diseases and disorders. The company is dedicated to creating innovative treatments for conditions such as overactive bladder and irritable bowel syndrome. Its lead clinical-stage product candidate, OP-233, targets stress urinary incontinence, a condition characterized by involuntary urine loss during physical activities that exert pressure on weakened pelvic floor muscles or urethral sphincters. Through its research and development efforts, Outpost Medicine aims to address significant unmet medical needs in these areas.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, focused on the development and commercialization of innovative oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Founded in 2011, the company’s lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a condition characterized by elevated urinary oxalate levels that can lead to kidney stones and chronic kidney disease. Additionally, Allena is developing ALLN-346, a novel enzyme intended to address hyperuricemia in patients with moderate to severe chronic kidney diseases. By targeting metabolic disorders associated with the accumulation of harmful metabolites, Allena Pharmaceuticals aims to provide effective treatments for patients facing serious health challenges.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

Calibrium is a privately-held biopharmaceutical company dedicated to the development of innovative drug candidates aimed at treating diabetes and related metabolic diseases. Co-founded by Fritz French, who serves as Chief Executive Officer, and Richard DiMarchi, PhD, the company's Chief Scientific Officer, Calibrium is focused on advancing its portfolio to address pressing health challenges associated with metabolic disorders.

AnaptysBio is a clinical-stage biotechnology company focused on developing therapeutic antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company's pipeline includes immune cell modulating antibodies such as rosnilimab, a PD-1 agonist in Phase 2b trials for rheumatoid arthritis and ulcerative colitis, and ANB032, a BTLA agonist in Phase 2b trial for atopic dermatitis.

Collegium Pharmaceutical is a specialty pharmaceutical company focused on developing proprietary, late-stage products that address non-medical use and abuse of prescription drugs through tamper-resistant formulations and extended-release delivery using its patent-protected DETERx platform. The company markets Xtampza ER, an abuse-deterrent extended-release oxycodone, and Nucynta products, including extended-release and immediate-release formulations of tapentadol for long- and short-term pain management. Its portfolio also includes Jornay as part of its product lineup, reflecting a strategy to expand applications of the DETERx technology. Headquartered in Stoughton, Massachusetts.

Merganser Biotech, Inc. is a biotechnology company focused on developing innovative medicines for rare hematological and iron overload diseases, including hemochromatosis, polycythemia vera, and beta thalassemia. Established in 2011 and headquartered in King of Prussia, Pennsylvania, the company specializes in creating hepcidin mimetic peptides aimed at regulating iron metabolism and addressing ineffective erythropoiesis. Through its research and development efforts, Merganser Biotech strives to provide effective treatments that enhance patient outcomes in the management of these complex conditions.

Laguna Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and marketing of small molecule pharmaceuticals, specifically targeting the treatment of atrial fibrillation (AF) and atrial flutter (AFL). The company, originally established as ChanRx Corp. in 2006, rebranded to its current name in February 2015. With its headquarters in La Jolla, California, Laguna Pharmaceuticals is dedicated to advancing therapeutic options for patients suffering from these common cardiac conditions, which can lead to serious health complications such as heart attacks and strokes.

Cidara Therapeutics is a biotechnology company dedicated to developing novel anti-infectives. Its primary focus is rezafungin acetate, an antifungal for treating serious invasive fungal infections. Additionally, it advances the Cloudbreak platform to develop antiviral therapies using Fc-conjugates.

Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company based in Newton, Massachusetts, focused on the development and commercialization of innovative oral enzyme therapeutics for rare and severe metabolic and kidney disorders. Founded in 2011, the company’s lead product candidate, reloxaliase, is currently undergoing a pivotal Phase 3 clinical program aimed at treating enteric hyperoxaluria, a condition characterized by elevated urinary oxalate levels that can lead to kidney stones and chronic kidney disease. Additionally, Allena is developing ALLN-346, a novel enzyme intended to address hyperuricemia in patients with moderate to severe chronic kidney diseases. By targeting metabolic disorders associated with the accumulation of harmful metabolites, Allena Pharmaceuticals aims to provide effective treatments for patients facing serious health challenges.

Imago BioSciences, Inc. is a clinical-stage biotechnology company based in Redwood City, California, founded in 2012. The company specializes in developing novel small molecule therapeutics aimed at treating hematologic diseases, including myelodysplastic syndromes, acute myelogenous leukemia, and other conditions associated with bone marrow failure. Central to its research is the enzyme lysine-specific demethylase 1 (LSD1), which is involved in the regulation of blood cell production. Imago BioSciences is focused on translating advanced scientific insights into transformative therapies that can alter the course of disease, thereby enhancing the quality and longevity of life for patients. Its lead product candidate, Bomedemstat, is an orally administered LSD1 inhibitor currently under evaluation for its potential to modify disease progression in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers.

VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company based in Seattle, Washington, founded in 2006. The company specializes in developing and commercializing immunotherapies that target Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Its lead investigational drug, Motolimod, aims to activate the immune system by stimulating myeloid dendritic cells, monocytes, and natural killer cells to combat cancer. VentiRx's product pipeline includes VTX-2337, a small molecule TLR8 agonist targeting solid tumors and various cancers, as well as VTX-1463 for treating allergies. The company also explores TLR8 antagonists for autoimmune diseases and other compounds that may serve as vaccine adjuvants. VentiRx has a strategic collaboration with Celgene Corporation to further its research and development efforts.

Cidara Therapeutics is a biotechnology company dedicated to developing novel anti-infectives. Its primary focus is rezafungin acetate, an antifungal for treating serious invasive fungal infections. Additionally, it advances the Cloudbreak platform to develop antiviral therapies using Fc-conjugates.

Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing targeted therapies for hematology and oncology patients. Founded in 2003 and headquartered in Vancouver, Canada, the company focuses on delivering innovative treatments for rare forms of cancer. Its lead drug candidate, momelotinib, is a selective inhibitor of JAK1, JAK2, and ACVR1, which has been evaluated in two completed Phase 3 trials for myelofibrosis. In addition, Sierra is advancing SRA737, an inhibitor of Checkpoint kinase 1 currently undergoing Phase 1/2 clinical trials, and SRA141, an inhibitor of cell division cycle 7 kinase in preclinical development. Through its scientific expertise and evidence-based approach, Sierra Oncology aims to transform cancer treatment paradigms and improve patient outcomes.

PowerVision, Inc. is a medical device company based in Belmont, California, focused on developing advanced intraocular lenses (IOLs) designed to restore vision for individuals affected by presbyopia and cataracts. Established in 2002, the company has created the FluidVision accommodating intraocular lens technology, which simulates the natural function of a healthy eye. This innovative lens utilizes a small amount of fluid to adjust its shape dynamically, allowing for clear vision at various distances. PowerVision aims to address the vision challenges faced by millions, particularly the over 20 million individuals in the U.S. with cataracts and the more than 90 million affected by presbyopia. The FluidVision lens represents a significant advancement in vision correction, potentially freeing patients from the need for glasses or other vision correction methods. In 2019, PowerVision was acquired by Alcon Laboratories, Inc.

Ignyta, Inc. is a biotechnology company focused on discovering, developing, and commercializing molecularly targeted therapies aimed at treating cancer and autoimmune diseases. Established in 2011 and based in San Diego, California, Ignyta is dedicated to advancing personalized medicine by integrating therapeutic approaches with companion diagnostics. Its notable products include entrectinib, a tyrosine kinase inhibitor targeting various receptor proteins, and RXDX-105, which is designed for RET-driven solid tumors. The company seeks to improve treatment outcomes by identifying patients most likely to benefit from specific therapies through biomarker-based diagnostics. In 2018, Ignyta became a subsidiary of Roche Holdings, further enhancing its capabilities in precision medicine.

PreCision Dermatology is a rapidly growing company dedicated to advancing skincare through innovative therapies. It focuses on developing products that enhance the delivery of active ingredients to the skin, reducing side effects and strengthening the skin's natural barrier. The company's portfolio addresses various dermatological conditions like atopic dermatitis, acne, and rosacea. PreCision Dermatology expands its offerings through internal research, acquisitions, licensing agreements, and strategic partnerships.